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Abstract
Introduction: Checkpoint kinase 2 (CHEK2) is a moderate penetrance breast cancer risk gene, whose truncating
mutation 1100delC increases the risk about twofold. We investigated gene copy-number aberrations and gene-
expression profiles that are typical for breast tumors of CHEK2 1100delC-mutation carriers.
Methods: In total, 126 breast tumor tissue specimens including 32 samples from patients carrying CHEK2 1100delC
were studied in array-comparative genomic hybridization (aCGH) and gene-expression (GEX) experiments. After
dimensionality reduction with CGHregions R package, CHEK2 1100delC-associated regions in the aCGH data were
detected by the Wilcoxon rank-sum test. The linear model was fitted to GEX data with R package limma. Genes
whose expression levels were associated with CHEK2 1100delC mutation were detected by the bayesian method.
Results: We discovered four lost and three gained CHEK2 1100delC-related loci. These include losses of 1p13.3-31.3,
8p21.1-2, 8p23.1-2, and 17p12-13.1 as well as gains of 12q13.11-3, 16p13.3, and 19p13.3. Twenty-eight genes
located on these regions showed differential expression between CHEK2 1100delC and other tumors, nominating
them as candidates for CHEK2 1100delC-associated tumor-progression drivers. These included CLCA1 on 1p22 as
well as CALCOCO1, SBEM, and LRP1 on 12q13. Altogether, 188 genes were differentially expressed between CHEK2
1100delC and other tumors. Of these, 144 had elevated and 44, reduced expression levels.
Our results suggest the WNT pathway as a driver of tumorigenesis in breast tumors of CHEK2 1100delC-mutation
carriers and a role for the olfactory receptor protein family in cancer progression. Differences in the expression of
the 188 CHEK2 1100delC-associated genes divided breast tumor samples from three independent datasets into two
groups that differed in their relapse-free survival time.
Conclusions: We have shown that copy-number aberrations of certain genomic regions are associated with CHEK2
mutation 1100delC. On these regions, we identified potential drivers of CHEK2 1100delC-associated tumorigenesis,
whose role in cancer progression is worth investigating. Furthermore, poorer survival related to the CHEK2 1100delC
gene-expression signature highlights pathways that are likely to have a role in the development of metastatic
disease in carriers of the CHEK2 1100delC mutation.
Introduction
Large-scale gene-expression (GEX) profiling by DNA
microarrays has become a routine method in breast
cancer research. It has been widely used in tumor-sub-
type classification, and gene signatures predicting
clinical outcome have been defined in a number of
studies [1-8].
The tumor genome is characterized by multiple trans-
locations as well as gains and losses of chromosomal
regions. Overall chromosomal instability is a result of
arbitrary processes that take place during tumor pro-
gression, like breakage-fusion-bridge cycles [9], sponta-
neous breaks [10], and aberrant segregation of
chromosomes in mitosis [11]. The cells that by chance
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more-malignant subpopulation of cancer cells.
Array-comparative genomic hybridization (aCGH)
enables fine mapping of the locations of chromosomal
breakpoints and detection of copy number on each loca-
tion [12,13]. Combined aCGH and GEX profiling repre-
sents a valuable tool. aCGH can detect the events that
have been selectively advantageous during the tumor
progression as consistently gained or lost regions across
a set of samples. GEX can further highlight the driver
genes within these regions, revealing the ones whose
expression levels have changed [14].
Understanding cellular processes that drive tumori-
genesis is essential to select the optimal treatment for
cancer [15]. Breast cancer can be divided into several
subtypes that are characterized by differences in histo-
pathologic features [16] as well as in genomic copy
number [17,18] and gene-expression profiles [1,5,19,20].
These differences ultimately derive from different biolo-
gic pathways that drive the tumor progression. For
example, tumors from BRCA1- and BRCA2-mutation
carriers exhibit distinct copy-number and gene-expres-
sion profiles and cluster into separate breast cancer sub-
types [2,18,21], suggesting that events taking place
during tumorigenesis are different and are influenced by
the underlying inherited vulnerability of the key players,
known as breast cancer tumor-suppressor genes. This
raises a possibility also that moderate-penetrance muta-
tions, such as CHEK2 1100delC, could be associated
with certain genomic changes and gene-expression
profiles.
CHEK2 (checkpoint kinase 2) is an intermediate-level
breast cancer risk gene, whose truncating mutation
1100delC doubles the risk of unselected women [22],
but gives rise to much higher risk for women who
have a family history of breast cancer [23]. Frameshift
mutation 1100delC causes premature translation stop
at codon 381 in the middle of the kinase domain of
the protein [24]. Truncated protein is highly unstable
[25,26] as well as the mutated mRNA, which is rapidly
degraded through nonsense-mediated mRNA decay
[27].
The well-known role of CHEK2 is to regulate cellular
responses to DNA double-strand breaks (DSBs). ATM
(ataxia telangiectasia mutated) phosphorylates CHEK2
in response to DNA damage. This leads to CHEK2
homodimerization, resulting in an active kinase whose
targets include cell-cycle regulators CDC25A, CDC25C,
PLK and E2F1, BRCA1 involved in homologous recom-
bination, as well as the master coordinator of apoptosis,
TP53 [28]. Recently CHEK2 was reported to be involved
also in regulation of the proper assembly of the mitotic
spindle [29]. Even partial loss of CHEK2 activity was
sufficient to cause chromosomal instability.
Loss of 22q, where the CHEK2 locus resides, is a com-
mon event in breast cancer [30,31]. Tumors from
patients carrying CHEK2 mutation 1100delC show
reduced CHEK2 protein activity that can partly be
explained by the loss of the wild-type allele in tumor
cells [25,32]. However, loss of heterozygocity (LOH)
does not comprehensively explain CHEK2 1100delC-
related tumorigenesis, and likely also other molecular
mechanisms exist, through which CHEK2 deficiency
contributes to malignant development [26,33]. CHEK2
1100delC mutation is associated with estrogen receptor
(ER) positive and higher grade tumors, as well as with
bilateral disease [34,35]. Breast cancer patients with
CHEK2 1100delC have been found to have a poorer dis-
ease-free and overall survival [34,36], and this may
partly be due to a disadvantageous response to treat-
ment that causes DNA damage [37,38].
Here we report the first study investigating CHEK2
1100delC-related tumorigenesis by comparing gene-
expression profiles and genomic changes in breast
tumors of CHEK2 1100delC-mutation carriers to those
of patients negative for any known germline mutations.
As CHEK2 deficiency is not restricted to tumors of
1100delC-mutation carriers [25], similar copy number
aberrations and gene-expression changes could also be
present in the tumors of noncarriers, but enriched in
the mutation carriers. The genomic aberrations as well
as activated or silenced genes and pathways characteris-
tic for CHEK2 1100delC mutation-carrier tumors are
good candidates for CHEK2 1100delC-related tumor-
progression drivers to be investigated further. Finally,
we investigated the clinical significance of the discovered
CHEK2 1100delC gene-expression signature.
Materials and methods
Patients and tumor tissue samples
In total, 126 tumor tissue samples from 121 breast can-
cer patients negative for BRCA1, BRCA2,o rTP53 germ-
line mutations were obtained from Helsinki University
Central Hospital, Department of Pathology. Thirty of
the patients carried germline mutation CHEK2
1100delC. Tumor characteristics are described in detail
in additional files (Additional file 1, Additional file 2).
The study was carried out with the permission from
the Helsinki University Central Hospital Ethics Commit-
tee (Dnro207/E9/07) and with written informed con-
sents from the patients. Both processed and raw data of
aCGH and GEX experiments are available in Gene
Expression Omnibus database [GEO: GSE24707] [39].
Gene-expression microarrays
Labeled tumor cDNA samples and reference samples
(Universal Human RNA; Stratagene, La Jolla, CA, U.S.
A.) were hybridized to custom-made cDNA microarrays
Muranen et al. Breast Cancer Research 2011, 13:R90
http://breast-cancer-research.com/content/13/5/R90
Page 2 of 12[GEO: GPL5345] produced at SCIBLU Genomics Cen-
tre, Lund University, Sweden, as described earlier [40].
Two samples were hybridized twice, and one sample, 3
times for quality control. Nucleic acid extraction, data
acquisition, and preprocessing are described in detail in
additional files (Additional file 2, Additional file 3).
Comparative genomic hybridization microarrays
The tiling-resolution genomic BAC (bacterial artificial
chromosome) arrays [GEO: GPL4723] were described in
detail previously [40], along with the slide treatment and
hybridization protocol. Further details on nucleic acid
extraction, hybridizations, data acquisition, preproces-
sing, and quality control are described in detail in addi-
tional files (Additional file 2, Additional file 3,
Additional file 4).
aCGH data analysis
Data analysis was carried out in R software environment
for statistical computing version 2.10. Soft calls (that is,
loss, normal, and gain with probabilities) were calculated
for each clone of the segmented data with the package
CGHcall [41]. Sequences of clones with constant calls
across all samples or across the CHEK2 1100delC-muta-
tion carrier samples were defined by using R package
CGHregions [42], allowing maximal information loss of
2.5%. Regions defined across all samples were tested for
significant differences in calls between CHEK2
1100delC-mutation carrier and other tumors with the
Wilcoxon rank-sum test, and those with nominal P
values less than 0.01 were considered to be of interest.
To assure that the results were not confounded by the
estrogen receptor (ER) status, we performed similar ana-
lysis comparing ER-positive and ER-negative tumors to
discover ER-associated regions. Regions defined only on
basis of the CHEK2 1100delC-mutation carrier tumor
samples by CGHRegions analysis were used primarily to
explore the copy number of the genomic region cover-
ing the CHEK2 locus.
Gene-expression data analysis
Gene-expression data analysis was carried out in R ver-
sion 2.10 package limma [43-45]. For comparison of
CHEK2 1100delC carrier and other tumors using multi-
variate analysis, a linear model with six covariates was
fitted in the data. Specifically, as ER status is one of the
most important tumor characteristics, which has a great
impact also on the tumor gene-expression profile, we
included it as a covariate in the multivariate linear
model estimating the associations of the covariates on
gene-expression levels in our dataset. The algorithm
estimated which proportion of gene-expression changes
was associated with CHEK2-mutation carrier status
(independent of ER status), and simultaneously, which
proportion of gene expression was associated with ER
status (independent of CHEK2 mutation status) and
similarly for all covariates. In addition to the tumor ER
status and CHEK2 1100delC, the six covariates included
a family history of breast cancer, tumor histopathologic
types ductal or lobular, as well as NQO1 rs1800566 gen-
otype, for its rare allele has been associated with poor
breast cancer survival [46], and the gene is likely to have
a role in tumor progression. Frequencies of other histo-
pathologic types were too low to have any detectable
effect. For five samples, data for all covariates was not
available, and these samples were omitted from the mul-
tivariate analysis. Statistical significance of differentially
expressed genes was assessed with the empiric bayesian
method. Genes with nominal P values less than 0.05
were considered to be differentially expressed. This
resulted in a set of 862 genes that were used for func-
tional enrichment analysis. The 188 genes used in the
survival signature were selected by using a stricter P-
value threshold, 0.01.
Functional annotation of differentially expressed genes
Functional annotation and enrichment analyses were
carried out with the DAVID microarray functional
annotation tool [47] and with the AmiGO [48] version
1.7 from the Gene Ontology [49,50] database during the
period of July to October 2010, as well as from pub-
lished literature. We also compared the CHEK2
1100delC-related list of 188 genes with previously pub-
lished breast cancer gene-expression signatures designed
for either subtype classification or survival prediction to
detect possible similarities [1-8].
Survival analysis of public datasets
The survival effect of 188 CHEK2 1100delC-related
genes was studied in a larger Helsinki gene-expression
dataset of 183 unselected and familial breast tumor sam-
ples [GEO: GSE24450] as well as in three public datasets
with the approach previously suggested [51]. The Hel-
sinki dataset consisted of 151 breast cancer patients col-
lected in three unselected cohorts previously described
[35,46,52] and 32 additional familial breast cancer cases.
The three public datasets consisted of two Swedish
cohorts, one from Uppsala [GEO: GSE3494; GEO:
GSE4922] [53,54] and another from Stockholm [GEO:
GSE1456] [55]. Differences in sample selection and sur-
vival-analysis end points are summarized in additional
files (Additional file 5). Of the 188 CHEK2 1100delC-
related genes, 131 (69.7%) were present on the array
used for the Helsinki dataset, and 108 (57.4%) on the
array used for all Swedish datasets. The gene-expression
matrices for the available genes were used as input of k-
means clustering implemented in R v.2.11, with k = 2
and using 100,000 iterations to split the samples of each
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nature genes. Stabilization of the k-means results was
secured by setting a random-number-generator schema
for the initial k-means iteration. Differences in survival
between the two groups of each dataset were evaluated
by the log-rank test, and the Kaplan-Meier survival
curves were generated for visualization.
Results
Areas with differing copy number
In the following sections, we use “copy number” to refer
to the following three states: loss, normal, or gain. Seven
chromosomal locations were found to differ in copy
number between the CHEK2 1100delC-mutation carrier
and other tumors, as defined by P values less than 0.01
when tested with the Wilcoxon rank-sum test. CHEK2
1100delC-associated regions included wide loss of
1p13.3-31.3, losses of 8p21.1-2, 8p23.1-2, and 17p12-
13.1, as well as gains of 12q13.11-3, 16p13.3, and
19p13.3 (Figure 1, Table 1). The association with the
CHEK2 mutation was not confounded by the ER status
(data not shown).
The genomic region of CHEK2 locus in mutation-carrier
tumors
The genomic region, which covered the CHEK2 locus
and where all CHEK2 1100delC samples had consistent
calls, as defined by CGH regions analysis, spanned three
successive BAC clones, almost 2 kb, and five genes. This
region was lost in six, gained in four, and of normal
copy number in 12 of the CHEK2 1100delC samples.
Gene-expression analysis
To estimate the independent effect of CHEK2 1100delC,
we fitted a multivariate linear model on the gene-
expression data and included the tumor ER status and
histopathologic type as well as patient’s family history of
breast cancer and rs1800566 genotype as covariates.
Comparison of gene-expression data from CHEK2
1100delC-mutation carrier and other tumors resulted in
188 (Additional file 6) and 862 differentially expressed
genes with nominal P-value thresholds 0.01 and 0.05,
respectively. Fold changes ranged from half to almost
fourfold (Additional file 7). In the gene set resulting
from the more stringent P-value cut-off, 144 genes had
increased, and 44, reduced expression, and in the total
of 862 genes, the respective numbers were 522 and 340.
Enriched functional groups among differentially
expressed genes
The most significantly enriched functional group among
the set of 862 differentially expressed genes was olfac-
tion: altogether, 35 olfactory receptors (OR), 34 of them
having elevated expression in CHEK2 1100delC tumors,
were found (Additional file 7, Additional file 8). The 35
OR genes were located on 10 different chromosomes.
Of these, 16 resided on chromosome 11, clustering in
two blocks: 10 genes on 11p15.4 and five genes on a
region flanking the centromere (11p11.2-11q12.1).
Furthermore, we identified two chromosomal regions
where more than two differentially expressed OR were
located together with other differentially expressed
genes, 6p21.33-6p22.1 and 12q13.11-12q13.3.
Other interesting enriched biologic entities among the
set of genes with elevated expression (Additional file 8)
were the interrelated WNT signaling pathway, cell adhe-
sion, and calcium binding (Additional file 9). Also tran-
scription regulation-related genes and members of zinc-
finger, Ras-GEF, and EGF families were enriched.
In the set of genes with lower expression in CHEK2
1100delC tumors, the enriched functions (Additional file
10) included DNA modification, transcription, mRNA
processing, ribosome, and translation. Additionally, we
retrieved several genes related to mitochondria and cel-
lular respiration, as well as to the cytoskeleton. Some
genes involved in the recognition of DNA damage were
downregulated as well.
Differentially expressed genes on regions with differing
copy numbers
Significantly differentially expressed genes were found
on four of the seven CHEK2 1100delC-associated
regions: those on chromosomes 1, 8, 12, and 16. The
overall level of gene expression in the CHEK2 1100delC-
associated regions was not consistent with the corre-
sponding copy number, which was as expected, because
only partial overlap was noted between the sample sets
in aCGH and GEX experiments. However, we identified
a handful of genes as candidates driving CHEK2
Chr1 Chr1
Chr8
Chr12
Chr8
Chr12
Chr18
Chr17
Chr18
Chr17
Chr19 Chr19
Figure 1 Regions of differing copy number between CHEK2
1100delC-mutation carriers and controls. Chromosomal (Chr)
locations of lost regions typical of CHEK2 1100delC-mutation carriers
are marked with green boxes, and gained regions, with red boxes.
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nin-mediated transcription-related CALCOCO1 [56],
breast cancer poor-prognosis marker SBEM [57,58], and
SMARCC2, a member of SWI/SNF chromatin-remodel-
ing complex interacting with BRCA1 [59]. All were
located on 12q13 and showed elevated expression levels
in CHEK2 1100delC tumors.
CLCA1 on 1p22.3 was among the top-ranking genes
of differential expression, but its expression level was
inconsistent with the CHEK2 1100delC typical copy
number, for the region was frequently lost (Table 2).
Survival effect of 188 differentially expressed genes
We further tested whether the 188 CHEK2 1100delC-
related genes (Additional file 7) might be associated
with breast cancer prognosis. Based on their expression
levels in the Helsinki and Uppsala gene-expression data
sets, it was possible to divide the tumors into groups
with different survival rates of the patients. Also in the
third one, the smaller Stockholm dataset, there was evi-
dence for survival difference, but it did not reach statis-
tical significance. (Figure 2). Altogether, the CHEK2
1100delC gene-expression signature was associated with
more rapid relapse of the disease in all three sample
sets. In the largest data set (Uppsala), the CHEK2
1100delC signature also significantly also predicted 10-
year breast cancer-specific survival.
Little similarity was seen between the gene list of 188
CHEK2 1100delC-associated genes and eight gene lists
from previously published gene-expression signatures
predicting survival or breast cancer subtype (Table 3).
Not more than about 1% of genes from any previously
published gene list were shared by the CHEK2
1100delC-related list.
Discussion
We investigated the genomic copy number and gene-
expression profiles of breast tumors of CHEK2 1100delC-
mutation carriers. We aimed to identify patterns enriched
in the CHEK2 1100delC group compared with the control
group, to understand tumorigenesis, to which the CHEK2
germline deficiency predisposes. We discovered two larger
and five more narrow genomic regions whose copy-num-
ber aberrations were typical of CHEK2 1100delC tumors.
We also identified 862 genes whose expression levels dif-
fered between the two groups of tumors, suggesting differ-
ential activity of especially WNT and olfactory pathways
in these groups. Furthermore, we observed that the
CHEK2 1100delC gene-expression signature is related to
increased risk of breast cancer relapse.
Among the genes with lower expression levels in
CHEK2 1100delC tumors, we observed several genes
associated with centrosomes and the cytoskeleton or
with DNA-damage signaling and apoptosis, as expected,
owing to the role of CHEK2 in response to DNA
damage and in centrosome assembly. The apoptosis-
related genes included pro-apoptotic BAX and BAD and
DNA damage sensor PARP1.
BCL-2 family proteins, including BAD and BAX, are
involved in the regulation of the normal breast tissue
Table 1 Chromosomal regions with differing copy number between CHEK2 1100delC-mutation carriers and others
Chromosome Start End Clones Sum of clones Length Cytoband P value
1 63762320 75867880 109 410 46865220 1p13.3-31.3 0.0031
1 76025260 87854764 110 0.0004
1 87964559 98030482 81 0.0001
1 98201778 110627540 110 0.0004
8 3329536 5083904 26 46 4279506 8p21.1-2 0.0062
8 5292190 6859255 15 0.0027
8 7041464 7609042 5 0.0066
8 24208215 29092984 35 41 5366218 8p23.1-2 0.0035
8 29293167 29574433 6 0.0064
12 46370995 47105108 10 103 9563151 12q13.11-3 0.0018
12 47191262 49654440 21 0.0022
12 49858115 51459707 21 0.0065
12 51492453 52261807 9 0.0025
12 52382320 54215964 23 0.0009
12 54367089 55934146 19 0.0044
16 11139 3142783 23 23 3131644 16p13.3 0.0091
17 9578676 15297799 54 54 5719123 17p12-13.1 0.0025
19 2122188 4798764 17 17 2676576 19p13.3 0.0045
Areas on chromosomes 1, 8, and 12 consist of multiple non-overlapping regions with differing copy numbers, whereas areas on chromosomes 16, 17, and 19
consist of single regions. Each row represents one region with constant calls across all samples. Sum of clones and length columns give the number of clones on
all regions of each area and the total length of the area, respectively.
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disturbed in malignant tissue, and reduced expression of
B A Da n dB A Xi sa s s o c i a t e dw i t hp o o rp r o g n o s i si n
breast cancer. All BCL-2 proteins regulate the mito-
chondrial apoptotic pathway. BAX induces apoptosis by
increasing the permeability of the mitochondrial outer
membrane to release cytochrome c. BAD is an upstream
regulator of several pro- and antiapoptotic BCL-2 family
proteins, BAX among them [60]. BAX is a transcrip-
tional target of TP53 [61] and therefore also a down-
stream target of CHEK2. Its downregulation could be
seen as a consequence of reduced CHEK2 activity, but
at the same time, as a survival mechanism of the tumor
cells.
aCGH analysis highlighted seven genomic locations,
whose copy-number aberrations were enriched in
tumors of CHEK2 1100delC-mutation carriers. These
included losses of the proximal part of 1p, two regions
on 8p and a narrow region in the middle of 17p as well
as gains of the proximal region on 12q and short distal
regions on 16p and 19p. Loss of 8p is a common aberra-
tion in breast tumors, and several loci on 8p have been
suggested to harbor tumor-suppressor genes [62]. Our
data support these reports. The entire chromosome arm
8p was frequently lost in both CHEK2 1100delC and
other tumors, but losses of certain sections of the arm
were more frequent in CHEK2 1100delC tumors. Simi-
larly, a region distal to 1p31 has been suggested to har-
bor tumor-suppressor genes, because it is commonly
lost in breast and other solid tumors, and the loss is an
early event in breast carcinogenesis [63]. Interestingly,
this region covers only a small proportion of the
CHEK2 1100delC associated more proximal to 1p13.3-
31.3. Expression of a handful of genes located on
1p13.3-31.3 differed between CHEK2 1100delC-carrier
tumors, the most significant of them being the calcium-
activated chloride channel, CLCA1. CLCA1 and its three
paralogs CLCA2,- 3, and -4, all reside on 1p22.3. CLCA2
that shares 63% sequence similarity with CLCA1 [64]
has been suggested to be a breast cancer tumor-suppres-
sor gene [65]. The CLCA1 locus was lost in one third of
CHEK2 1100delC tumors but only in 3.5% of other
tumors. Conversely, CLCA1 gene expression was signifi-
cantly higher in CHEK2 1100delC tumors. From our
data, we cannot state whether the loss of the CLCA1
locus and elevated expression were simultaneous events.
They could also be alternative events both affecting
CLCA1 normal function.
12q13 is a locus of a WNT gene cluster, hosting genes
WNT10B and WNT1, as well as WNT pathway modi-
fiers CALCOCO1 and LRP1 [66]. It is also a locus for a
cluster of olfactory receptor genes. The results from
GEX and aCGH analyses converge to highlight the
importance of these two pathways. Expression of alto-
gether 15 genes related to the WNT pathway was ele-
vated. These included such central players as WNT2
growth factor and c-MYC cellular oncogene. Expression
differences of olfactory receptor genes were even more
pronounced: up to 34 OR genes had higher expression
in CHEK2 1100delC-mutation carriers than in the con-
trol samples.
In adult human breast tissue, WNT2 expression is
restricted to stromal cells, whereas in cancers, elevated
WNT2 expression has been detected also in epithelial
cells, suggestive of an autocrine signaling loop [67].
Furthermore, elevated WNT2 expression is a common
feature in breast carcinomas and breast cancer cell lines
[68,69]. It is associated with the epithelial mesenchymal
transition, metalloproteinase induction through EGFR
transactivation, invasive phenotype, and metastasis
[67,69,70]. The oncogene MYC is one of the transcrip-
tional targets of the WNT pathway, and it has been
Table 2 Differentially expressed genes on regions with
differential copy number
Gene
symbol
GEX: fold
change
GEX: P
value
Region aCGH: gain/
loss
CLCA1 1.8178 0.000007 chr1 Loss
DPH5 0.8254 0.0049 chr1 Loss
C1orf62 1.3277 0.0057 chr1 Loss
ATXN7L2 1.2804 0.007 chr1 Loss
DR1 0.8474 0.0108 chr1 Loss
TMED5 0.8728 0.0145 chr1 Loss
ALG14 0.8640 0.0389 chr1 Loss
LRRC8D 0.8854 0.0433 chr1 Loss
DEFA5 1.1076 0.0113 chr8 Loss
DUSP4 1.2724 0.0426 chr8 Loss
OR6C3 1.2558 0.0016 chr12 Gain
CALCOCO1 1.2579 0.0016 chr12 Gain
SBEM 3.0936 0.0217 chr12 Gain
OR6C2 1.1820 0.0485 chr12 Gain
LRP1 0.8171 0.0011 chr12 Gain
OR10AD1 1.2648 0.0061 chr12 Gain
CSAD 1.2758 0.0067 chr12 Gain
C12orf10 0.8867 0.0122 chr12 Gain
MYO1A 0.7468 0.0131 chr12 Gain
LALBA 1.2369 0.0187 chr12 Gain
ITGA7 1.2531 0.0201 chr12 Gain
OR9K2 1.4794 0.0231 chr12 Gain
KRT5 1.7237 0.0382 chr12 Gain
FAM112B 0.7840 0.0426 chr12 Gain
SMARCC2 1.1788 0.047 chr12 Gain
KIAA1924 0.8549 0.0156 chr16 Gain
NTHL1 0.8410 0.0233 chr16 Gain
KIAA1171 1.1890 0.0348 chr16 Gain
Five of eight differentially expressed genes on 1p13.3-31.3 show reduced
expression levels. On 12q13.11-3, 11 of 15 genes show elevated expression.
aCGH, array comparative genomic hybridization; GEX, gene expression.
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Figure 2 Breast cancer (BC)-related survival differences in three sample sets divided on the basis of the CHEK2 1100delC signature.
Expression levels of the CHEK2 1100delC-related genes divide breast tumors into groups of better and poorer prognosis. Significant differences in
overall or disease-free survival were detected in Helsinki and Uppsala cohorts, whereas in the Stockholm cohort, the differences were more
subtle. The difference between the curves was measured with the log-rank test.
Muranen et al. Breast Cancer Research 2011, 13:R90
http://breast-cancer-research.com/content/13/5/R90
Page 7 of 12shown to enhance its own expression by promoting
WNT signaling in tumors [71].
Elevated expression levels of WNT2, MYC,i t st r a n -
scriptional co-activator MAX, as well as several compo-
nents of the WNT pathway, suggest that the pathway
has a central role in CHEK2 1100delC-related tumori-
genesis. The genes with elevated expression were
involved in canonic and calcium-signaling branches of
the WNT pathway. Interestingly, the expression of
LEF1, the main transcription factor of the pathway, as
well as LRP1, a cell-surface co-receptor of WNT ligand,
was lower in CHEK2 1100delC tumors when compared
with others. This, together with elevated E cadherin
(CDH1) levels, implies that some balancing forces might
act in control of the WNT pathway in the CHEK2
1100delC tumors.
Olfactory receptors (ORs) form the biggest mammalian
gene family, with more than 800 genes present in the
human genome and only about 45% of them being func-
tional. ORs are located in clusters that are dispersed
across almost all chromosomes. Great interindividual
variation exists in the copy number of some OR genes,
as well as in the proportion of functional alleles, as a
result of low selection pressure [72,73]. ORs bind speci-
f i c a l l yaw i d er a n g eo fs m a l lc h e m i c a lc o m p o u n d s ,
including steroid hormones and their analogs, and func-
tion in odor recognition [74,75]. Until now, only one
OR gene, prostate-specific G-protein-coupled receptor
(PSGR/OR51E2), has been connected to cancer. PSGR is
activated by steroid hormones, and the activated recep-
tor has been found to suppress prostate tumor cell pro-
liferation through SAPK/JNK and p38 [75].
In addition to the neurons of the forebrain olfactory
bulb [76], ORs are widely expressed across different tis-
sues, but their functions in these locations remain
obscure. ORs have been proposed to be involved in cell-
cell recognition and in the organization of cells in devel-
oping tissues during embryogenesis [77], an analogous
function to the one that they have in the organization of
t h eo l f a c t o r yb u l b[ 7 8 ] .B u t ,s ince OR expression in dif-
ferent cell types does not show a clear pattern that would
argue for specific functionality, it has been suggested that
OR expression would partially result from transcriptional
activity of neighboring genes [79]. The existence of
neighboring driver genes is one possibility to explain the
elevated expression OR genes in CHEK2 1100delC breast
tumors. Our data do not strongly support it, although it
cannot be totally excluded. On the basis of our observa-
tions, we suggest that the role of the olfactory receptor
protein family in cancer cell proliferation and tissue inva-
sion should be investigated further, as these are the two
roles in which ORs have been previously implicated.
Converging evidence from the gene-expression and
aCGH datasets studied here had the potential to reveal
biologic functionalities and pathways that were relevant
in CHEK2 1100delC-related tumorigenesis. This study
concentrated on genomic-level changes that were asso-
ciated with the 1100delC germline mutation, whereas
previous studies have shed light on the CHEK2 protein
expression in breast tumors. The protein expression is
reduced or absent in the mutation-carrier tumors, but
mechanisms leading to this may vary, and LOH has
been reported for only part of 1100delC-carrier tumors
[25,26,32,33]. Here we found that the CHEK2 locus was
lost in fewer than one third of our mutation-carrier
samples and gained in some, with the majority not
showing evidence for copy-number variation. We have
also determined CHEK2 transcript levels in lymphoblas-
toid cell lines heterozygous for CHEK2 1100delC and
have shown that constitutive CHEK2 gene expression is
significantly reduced in cells from heterozygous carriers
of 1100delC (fold change, 0.73; two-sided Student t-test
P = 3.4 × 10
-7; Muranen et al, unpublished data). These
results support the hypothesis of haploinsufficiency
being a possible factor driving CHEK2 1100delC-related
tumorigenesis [80].
Table 3 Overlap between the 188 CHEK2 1100delC-associated genes and eight previously published gene-expression
signatures
Gene-expression signature Genes Overlap Proportion
SSP2003 [2] 500 5 0.010
SSP2006 [1] 306 2 0.007
PAM50 [5] 50 1 0.020
70 gene poor-prognosis signature [3] 70 0 0.000
76 gene metastasis signature [4] 76 0 0.000
Gene-expression grade index [6] 128 1 0.008
Recurrence score [7] 21 0 0.000
Recurrence predictor in tamoxifen-treated patients [8] 181 2 0.011
GO: proliferation [49,50] 1677 13 0.008
The first column contains names and references for the gene-expression signatures as well as the reference for proliferation-associated genes in the Gene
Ontology database (GO). The second to fourth columns indicate the number of genes included in the signature, the number overlapping with each signature,
and the 188 genes and proportion of genes of each signature among the 188 genes, respectively.
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1100delC signature of 188 genes and breast cancer
relapse. Gene-expression differences of these genes were
able to categorize patients into two groups that differed
in their risk of breast cancer relapse. Association was
observed in all three independent datasets, even though
the analysis end points differed slightly between the data
from different studies. In the largest dataset, the CHEK2
1100delC signature significantly predicted 10-year breast
cancer-specific survival. This result is consistent with
the previous reports suggesting that the 1100delC germ-
line genotype associates with worse survival for the car-
riers [36]. Further studies of larger materials will reveal
whether this might be due to a worse therapy response.
Little overlap was found between the CHEK2 1100delC
gene signature and previously published signatures. For
the gene-expression analysis here, a multivariate analysis
was used to identify CHEK2 1100delC-associated effects
that were independent of possible confounding effects,
especially the ER status, which is the most important
mediator of breast cancer biology and subtypes. The
number of genes shared between the published signa-
tures overall is very low, even though they have been
shown to perform equally well in predicting clinical out-
come. It has been suggested that the prediction capability
of these signatures is based on the presence of prolifera-
tion-associated genes [81]. Conversely, among the 188
CHEK2 1100delC-related genes, only 13 were associated
with proliferation. Altogether, this suggests that the
CHEK2 1100delC-associated signature of 188 genes is
distinct from other signatures specifically built to predict
breast cancer survival or classify tumors into subtypes
and reflects the downstream effects of the germline
CHEK2 1100delC mutation on tumor progression.
Conclusions
Altogether, differences between CHEK2 1100delC and
others tumors were not strong, but we were able to
point out chromosomal aberrations and gene-expression
changes that were more pronounced in the CHEK2
1100delC group. Furthermore, the poor survival asso-
ciated with the CHEK2 1100delC gene-expression signa-
ture suggests differential progression pathways in breast
tumors with defective CHEK2.O u rr e s u l t sc o n v e r g et o
highlight the importance of the WNT pathway as a dri-
ver of tumorigenesis in breast tumors of CHEK2
1100delC-mutation carriers. Functional studies are
needed to reveal the roles of different components of
the pathway in different stages of cancer progression.
Another interesting target for future investigation is the
role of olfactory receptor family in cancer progression.
Additional material
Additional file 1: Tumor characteristics of study samples. Numbers
of samples from estrogen-negative and -positive tumors, patients with or
without a family history of breast cancer, patients with different
rs1800566 genotypes, as well as tumors of different histologic and
molecular subtypes in groups of CHEK2 (checkpoint kinase 2)-mutation
carrier and other tumors for both gene-expression (GEX) and array-
comparative genomic hybridization (aCGH) datasets. Molecular subtypes
are defined on the basis of Immunohistochemistry results: Luminal A: ER
+/PR
+, HER2
-; Luminal B: ER
+/PR
+, HER2
+; HER2 positive: ER
-/PR
-, HER2
+;
Basal: ER
-/PR
-, HER2
-, EGFR
+; Other triple negative: ER
-/PR
-, HER2
-, EGFR
-.
All data were not available for every sample. EGFR, epidermal growth
factor receptor; ER, estrogen receptor; Her2, human epidermal growth
factor receptor 2; PR, progesterone receptor.
Additional file 2: Supplementary methods. [82-94].
Additional file 3: Unsupervised clustering of array-comparative
genomic hybridization (aCGH) and gene-expression (GEX) data. Left,
aCGH samples do not cluster according to any of the covariates. Instead,
the clustering is based on informative genomic regions and tumors’
overall copy-number profiles. Right, unsupervised hierarchical clustering
of gene-expression data suggests that estrogen receptor (ER) status and
family history of breast cancer have an impact on the tumor’s gene-
expression profile. The effect of the other variables is likely to be smaller.
Replicates that were used as a quality control cluster together as
expected. Positions of CHEK2 (checkpoint kinase 2), 1100delC-mutation
carrier and control (contr) tumors are indicated by the uppermost color
block. NQO1
- and NQO1
+ stand for samples with germline rs1800566
genotypes: homozygotes of the more common allele (CC) and
heterozygotes or homozygotes of the rarer allele (CT or TT), respectively.
Frequency of copy-number changes along the genome is depicted with
a color scale from blue to red. Blue, few; red, frequent copy-number
aberrations.
Additional file 4: Pair-wise correlation plot of aCGH (array-
comparative genomic hybridization) quality control (QC)
hybridizations. Heatmap of pair-wise correlation between the
hybridization from fresh frozen tissue sample (fresh) and the dye-swap
hybridizations from formalin-fixed paraffin-embedded (paraf) tissue.
Additional file 5: Sample-selection criteria and survival-analysis end
points in Uppsala, Stockholm, and Rotterdam cohorts.
Additional file 6: Hierarchical clustering of samples according to
188 differentially expressed genes. All but two CHEK2 (checkpoint
kinase 2) 1100delC-mutation carriers cluster together in two branches.
Estrogen receptor (ER) status of each sample, either positive or negative,
is indicated by the second color block.
Additional file 7: The 862 differentially expressed genes. Gene
identifiers (ID), chromosomal locations, fold change (FC), P value, and
Benjamini-Hochberg (BH) multiple testing corrected P value.
Additional file 8: Functional enrichment of differentially expressed
genes with elevated expression levels. The most frequent annotation
categories are involved in olfactory transduction, WNT pathway or zinc
finger, Ras-GEF, or EGF protein families. FDR, false discovery rate; Pop,
population.
Additional file 9: Differentially expressed genes associated with
WNT pathway, cell adhesion, or calcium. Columns “CHEK2 M” and
“other M” give average and range of expression values for each gene in
CHEK2 1100delC-mutation carrier and other tumor samples
correspondingly.
Additional file 10: Functional enrichment of differentially expressed
genes with reduced expression levels. The most frequent annotation
categories are involved in the protein-expression pathway, mitochondria,
or cytoskeleton. (Pop, population; FDR, false discovery rate).
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